In primary prostate cancer, the SPINK1+/ERG- phenotype accounts for 12.5%, the SPINK1+/ERG+ phenotype accounts for 16.7%, the SPINK1-/ERG+ phenotype accounts for 25.0%, and the SPINK1-/ERG- phenotype accounts for 45.8% of cases, and all prostate cancers expressing SPINK1 or ERG show PTEN deletion (93). This evidence concerns the gene ERG and prostate cancer.